Skip to results
Modify your search
NARROW
1-20 of 623
Subject: Medicinal Chemistry
Journal
Antibody Therapeutics
Launching in 2018, Antibody Therapeutics will publish the latest advances and challenges in the discovery, research, development, manufacturing and methodology of therapeutic antibodies for the global scientific community
Journal Article
ACCEPTED MANUSCRIPT
Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody–drug conjugates Open Access
Antibody Therapeutics, tbag011, https://doi.org/10.1093/abt/tbag011
Published: 13 March 2026
Journal Article
ACCEPTED MANUSCRIPT
Novel ADC and γδ T Cell Engager Targeting CDH17 for the Therapy of Gastrointestinal Cancers Open Access
Antibody Therapeutics, tbag012, https://doi.org/10.1093/abt/tbag012
Published: 12 March 2026
Journal Article
ACCEPTED MANUSCRIPT
Systematic functional screening of ITIM domains identifies potent inhibitory modules for CAR-T Open Access
Antibody Therapeutics, tbag010, https://doi.org/10.1093/abt/tbag010
Published: 11 March 2026
Journal Article
ACCEPTED MANUSCRIPT
Challenges and solutions for upstream processing of complex biologics Open Access
Antibody Therapeutics, tbag008, https://doi.org/10.1093/abt/tbag008
Published: 09 March 2026
Journal Article
ACCEPTED MANUSCRIPT
Preventing Physical and Chemical Degradation of the LABL-fc-MOGR5, a Bifunctional Peptide Inhibitor, with Formulation Development Approaches Open Access
Antibody Therapeutics, tbag005, https://doi.org/10.1093/abt/tbag005
Published: 24 February 2026
Journal Article
Durable disease control following treatment with ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, in femoral osteosarcoma with lung metastases after chemotherapy failure: a case report Open Access
Antibody Therapeutics, tbag007, https://doi.org/10.1093/abt/tbag007
Published: 19 February 2026
Journal Article
Analysis of the use of monoclonal antibodies in the treatment of Crohn’s disease Open Access
Antibody Therapeutics, tbag006, https://doi.org/10.1093/abt/tbag006
Published: 10 February 2026
Journal Article
Correction to: CAR NK cell therapy for solid tumors: potential and challenges Open Access
Antibody Therapeutics, Volume 9, Issue 1, January 2026, Page 100, https://doi.org/10.1093/abt/tbag004
Published: 02 February 2026
Journal Article
A glycoengineered anti-ROR1 antibody, GE-zilovertamab, selectively enhances antibody-dependent cellular cytotoxicity against chronic lymphocytic leukemia Open Access
Antibody Therapeutics, Volume 9, Issue 1, January 2026, Pages 70–75, https://doi.org/10.1093/abt/tbag001
Published: 15 January 2026
Journal Article
IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy Open Access
Antibody Therapeutics, Volume 9, Issue 1, January 2026, Pages 86–99, https://doi.org/10.1093/abt/tbag002
Published: 15 January 2026
Journal Article
A novel bispecific antibody targeting OX40L and TNFα for the targeted treatment of rheumatoid arthritis Open Access
Antibody Therapeutics, Volume 9, Issue 1, January 2026, Pages 76–85, https://doi.org/10.1093/abt/tbag003
Published: 15 January 2026
Journal Article
Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy Open Access
Antibody Therapeutics, Volume 9, Issue 1, January 2026, Pages 58–69, https://doi.org/10.1093/abt/tbaf026
Published: 22 December 2025
Journal Article
Recent advances in structural investigations of cancer antigen mesothelin and its interactions with therapeutic antibodies Open Access
Antibody Therapeutics, Volume 9, Issue 1, January 2026, Pages 38–57, https://doi.org/10.1093/abt/tbaf028
Published: 01 December 2025
Journal Article
Unique loop-structured CD19/CD22 bispecific CAR-T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma: an observational study Open Access
Antibody Therapeutics, Volume 9, Issue 1, January 2026, Pages 24–37, https://doi.org/10.1093/abt/tbaf027
Published: 20 November 2025
Journal Article
Assessing the therapeutic potential of a panel of novel VCAM-1 antibodies using microfluidic and three-dimensional in vitro models of vascular inflammation Open Access
Antibody Therapeutics, Volume 8, Issue 4, October 2025, Pages 350–363, https://doi.org/10.1093/abt/tbaf025
Published: 04 November 2025
Journal Article
The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity Open Access
Antibody Therapeutics, Volume 9, Issue 1, January 2026, Pages 13–23, https://doi.org/10.1093/abt/tbaf023
Published: 01 November 2025
Journal Article
RO4, a high-affinity humanized antibody against the juxtamembrane region of mesothelin for targeted cancer therapy Open Access
Antibody Therapeutics, Volume 9, Issue 1, January 2026, Pages 1–12, https://doi.org/10.1093/abt/tbaf022
Published: 30 October 2025
Journal Article
Overcoming antigen tolerance to develop GB22–45-2, an anti-DKK1 antibody for gastric cancer Open Access
Antibody Therapeutics, Volume 8, Issue 4, October 2025, Pages 336–349, https://doi.org/10.1093/abt/tbaf024
Published: 30 October 2025
Journal Article
Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design Open Access
Antibody Therapeutics, Volume 8, Issue 4, October 2025, Pages 301–316, https://doi.org/10.1093/abt/tbaf020
Published: 17 October 2025
